{"id":"https://openalex.org/W2000818398","doi":"https://doi.org/10.1002/jps.20282","title":"Physicochemical Characterization of Ricobendazole: I. Solubility, Lipophilicity, and Ionization Characteristics","display_name":"Physicochemical Characterization of Ricobendazole: I. Solubility, Lipophilicity, and Ionization Characteristics","publication_year":2005,"publication_date":"2005-03-26","ids":{"openalex":"https://openalex.org/W2000818398","doi":"https://doi.org/10.1002/jps.20282","mag":"2000818398","pmid":"https://pubmed.ncbi.nlm.nih.gov/15793800"},"language":"en","primary_location":{"id":"doi:10.1002/jps.20282","doi":"https://doi.org/10.1002/jps.20282","is_oa":false,"landing_page_url":"https://doi.org/10.1002/jps.20282","pdf_url":null,"source":{"id":"https://openalex.org/S130661733","display_name":"Journal of Pharmaceutical Sciences","issn_l":"0022-3549","issn":["0022-3549","1520-6017"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Pharmaceutical Sciences","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5054049125","display_name":"Zimei Wu","orcid":"https://orcid.org/0000-0001-9777-0674","observed_orcids":["https://orcid.org/0000-0001-9777-0674"]},"institutions":[{"id":"https://openalex.org/I80281795","display_name":"University of Otago","ror":"https://ror.org/01jmxt844","country_code":"NZ","type":"education","lineage":["https://openalex.org/I80281795"]}],"countries":["NZ"],"is_corresponding":false,"raw_author_name":"Zimei Wu","raw_affiliation_strings":["School of Pharmacy, University of Otago, P.O. Box 913, Dunedin, New Zealand"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"School of Pharmacy, University of Otago, P.O. Box 913, Dunedin, New Zealand","institution_ids":["https://openalex.org/I80281795"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110131310","display_name":"Majid Razzak","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Majid Razzak","raw_affiliation_strings":["Bomac Laboratories Limited, Wiri Station Road, Auckland, New Zealand"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bomac Laboratories Limited, Wiri Station Road, Auckland, New Zealand","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085725409","display_name":"Ian G. Tucker","orcid":"https://orcid.org/0000-0002-3304-6377","observed_orcids":["https://orcid.org/0000-0002-3304-6377"]},"institutions":[{"id":"https://openalex.org/I80281795","display_name":"University of Otago","ror":"https://ror.org/01jmxt844","country_code":"NZ","type":"education","lineage":["https://openalex.org/I80281795"]}],"countries":["NZ"],"is_corresponding":false,"raw_author_name":"Ian G. Tucker","raw_affiliation_strings":["School of Pharmacy, University of Otago, P.O. Box 913, Dunedin, New Zealand"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"School of Pharmacy, University of Otago, P.O. Box 913, Dunedin, New Zealand","institution_ids":["https://openalex.org/I80281795"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5072720767","display_name":"Natalie J. Medlicott","orcid":"https://orcid.org/0000-0001-9778-1947","observed_orcids":["https://orcid.org/0000-0001-9778-1947"]},"institutions":[{"id":"https://openalex.org/I80281795","display_name":"University of Otago","ror":"https://ror.org/01jmxt844","country_code":"NZ","type":"education","lineage":["https://openalex.org/I80281795"]}],"countries":["NZ"],"is_corresponding":true,"raw_author_name":"Natalie J. Medlicott","raw_affiliation_strings":["School of Pharmacy, University of Otago, P.O. Box 913, Dunedin, New Zealand"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"School of Pharmacy, University of Otago, P.O. Box 913, Dunedin, New Zealand","institution_ids":["https://openalex.org/I80281795"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5072720767"],"corresponding_institution_ids":["https://openalex.org/I80281795"],"apc_list":{"value":3620,"currency":"USD","value_usd":3620},"apc_paid":null,"fwci":0.9719,"has_fulltext":false,"cited_by_count":54,"citation_normalized_percentile":{"value":0.67093652,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":98},"biblio":{"volume":"94","issue":"5","first_page":"983","last_page":"993"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10256","display_name":"Drug Solubulity and Delivery Systems","score":0.9932000041007996,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10256","display_name":"Drug Solubulity and Delivery Systems","score":0.9932000041007996,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11881","display_name":"Crystallization and Solubility Studies","score":0.0019000000320374966,"subfield":{"id":"https://openalex.org/subfields/2505","display_name":"Materials Chemistry"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T11460","display_name":"Analytical Methods in Pharmaceuticals","score":0.0015999999595806003,"subfield":{"id":"https://openalex.org/subfields/1602","display_name":"Analytical Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ricobendazole","display_name":"ricobendazole","score":1.0},{"id":"https://openalex.org/keywords/solubility","display_name":"solubility","score":0.8899999856948853},{"id":"https://openalex.org/keywords/lipophilicity","display_name":"lipophilicity","score":0.9819999933242798},{"id":"https://openalex.org/keywords/ionization","display_name":"ionization","score":0.7870000004768372},{"id":"https://openalex.org/keywords/ph-solubility-profile","display_name":"pH-solubility profile","score":0.902999997138977},{"id":"https://openalex.org/keywords/ampholytes","display_name":"ampholytes","score":0.7950000166893005},{"id":"https://openalex.org/keywords/pka","display_name":"pKa","score":0.7760000228881836},{"id":"https://openalex.org/keywords/hydroxypropyl-beta-cyclodextrin","display_name":"hydroxypropyl-\u03b2-cyclodextrin","score":0.9350000023841858},{"id":"https://openalex.org/keywords/inclusion-complexes","display_name":"inclusion complexes","score":0.7549999952316284},{"id":"https://openalex.org/keywords/partition-coefficient","display_name":"partition coefficient","score":0.9039999842643738},{"id":"https://openalex.org/keywords/antiparasitic-drugs","display_name":"antiparasitic drugs","score":0.6039999723434448}],"concepts":[{"id":"https://openalex.org/C155574463","wikidata":"https://www.wikidata.org/wiki/Q170731","display_name":"Solubility","level":2,"score":0.9415019750595093},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.8492130637168884},{"id":"https://openalex.org/C201399114","wikidata":"https://www.wikidata.org/wiki/Q898401","display_name":"Lipophilicity","level":2,"score":0.7214605808258057},{"id":"https://openalex.org/C2780471494","wikidata":"https://www.wikidata.org/wiki/Q146505","display_name":"Solvent","level":2,"score":0.5634673237800598},{"id":"https://openalex.org/C184651966","wikidata":"https://www.wikidata.org/wiki/Q906356","display_name":"Aqueous solution","level":2,"score":0.5417242050170898},{"id":"https://openalex.org/C2781213060","wikidata":"https://www.wikidata.org/wiki/Q49546","display_name":"Acetone","level":2,"score":0.46122461557388306},{"id":"https://openalex.org/C31057274","wikidata":"https://www.wikidata.org/wiki/Q863829","display_name":"Molar solubility","level":3,"score":0.4365845322608948},{"id":"https://openalex.org/C168191866","wikidata":"https://www.wikidata.org/wiki/Q4551818","display_name":"Stability constants of complexes","level":3,"score":0.41620516777038574},{"id":"https://openalex.org/C13965031","wikidata":"https://www.wikidata.org/wiki/Q243545","display_name":"Nuclear chemistry","level":1,"score":0.40431657433509827},{"id":"https://openalex.org/C43617362","wikidata":"https://www.wikidata.org/wiki/Q170050","display_name":"Chromatography","level":1,"score":0.34971708059310913},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.311767041683197}],"mesh":[{"descriptor_ui":"D000073738","descriptor_name":"2-Hydroxypropyl-beta-cyclodextrin","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000465","descriptor_name":"Algorithms","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002626","descriptor_name":"Chemistry, Pharmaceutical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002627","descriptor_name":"Chemistry, Physical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002851","descriptor_name":"Chromatography, High Pressure Liquid","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006863","descriptor_name":"Hydrogen-Ion Concentration","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008055","descriptor_name":"Lipids","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D012995","descriptor_name":"Solubility","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013056","descriptor_name":"Spectrophotometry, Ultraviolet","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015766","descriptor_name":"Albendazole","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D015766","descriptor_name":"Albendazole","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":true},{"descriptor_ui":"D019999","descriptor_name":"Pharmaceutical Solutions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047392","descriptor_name":"beta-Cyclodextrins","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D055598","descriptor_name":"Chemical Phenomena","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1002/jps.20282","doi":"https://doi.org/10.1002/jps.20282","is_oa":false,"landing_page_url":"https://doi.org/10.1002/jps.20282","pdf_url":null,"source":{"id":"https://openalex.org/S130661733","display_name":"Journal of Pharmaceutical Sciences","issn_l":"0022-3549","issn":["0022-3549","1520-6017"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Pharmaceutical Sciences","raw_type":"journal-article"},{"id":"pmid:15793800","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15793800","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of pharmaceutical sciences","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":30,"referenced_works":["https://openalex.org/W170835808","https://openalex.org/W249630810","https://openalex.org/W1503426215","https://openalex.org/W1510314201","https://openalex.org/W1537867938","https://openalex.org/W1877687377","https://openalex.org/W1973153695","https://openalex.org/W1983793298","https://openalex.org/W1989511197","https://openalex.org/W2009697466","https://openalex.org/W2015073280","https://openalex.org/W2020337784","https://openalex.org/W2028752363","https://openalex.org/W2034846891","https://openalex.org/W2037780003","https://openalex.org/W2038207631","https://openalex.org/W2057913937","https://openalex.org/W2066847123","https://openalex.org/W2067408544","https://openalex.org/W2075179133","https://openalex.org/W2082705552","https://openalex.org/W2084239487","https://openalex.org/W2086332458","https://openalex.org/W2097451863","https://openalex.org/W2122912627","https://openalex.org/W2138028952","https://openalex.org/W2164353890","https://openalex.org/W2283449839","https://openalex.org/W2322940080","https://openalex.org/W2410986093"],"related_works":["https://openalex.org/W2373956081","https://openalex.org/W2038020418","https://openalex.org/W2670439158","https://openalex.org/W2773160101","https://openalex.org/W4282926630","https://openalex.org/W1988913236","https://openalex.org/W4416421420","https://openalex.org/W4315778182","https://openalex.org/W287828772","https://openalex.org/W1482798901"],"abstract_inverted_index":null,"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":6}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}